Submitted by Anonymous (not verified) on 19 October 2026 - 13:43
Human medicines European public assessment report (EPAR): Vizimpro, dacomitinib, Date of authorisation: 02/04/2019, Revision: 4, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Vizimpro, dacomitinib, Date of authorisation: 02/04/2019, Revision: 4, Status: Authorised